HENLIUS (02696): Privatization plan falls through

HENLIUS (02696) and the offeror jointly announced that the merger was not approved at the H-share category shareholders' meeting. The special resolution approving the merger, as stated in the notice of the extraordinary general meeting, has been passed by the required majority of shareholders. However, since the merger was not approved at the H-share category shareholders' meeting, the special resolution will not take effect. The proposal to privatize the company will not proceed, and the listing status of the H-shares on the main board of the Stock Exchange will remain unchanged. As of the date of this joint announcement, Shanghai Fosun Pharmaceutical (through its subsidiary) holds a total of 59.56% of the company's shares. Although the merger has not been implemented, it will not affect Shanghai Fosun Pharmaceutical's controlling stake in the company, as the company will continue to be an important antibody technology platform for the Fosun Pharmaceutical Group. In the future, Shanghai Fosun Pharmaceutical will continue to support the group in deepening innovation in the field of biopharmaceuticals, expanding domestic and overseas markets, and further enhancing global competitiveness to achieve high-quality development.